Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Sildenafil

Unchecked
From Pharmacopedia
PDE5 Inhibitor
Sildenafil
Viagra, Revatio
Sildenafil was the first PDE5 inhibitor (FDA-approved 1998) and remains the prototype. Originally developed for angina; repurposed after a famous trial-side-effect observation. Same molecule is marketed as Revatio for pulmonary arterial hypertension at lower individual doses but higher daily totals.

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Pharmacokinetics

Absorption

~40%; reduced by high-fat meals.

Distribution

Plasma protein binding ~96%.

Metabolism

Hepatic via CYP3A4 (primary), CYP2C9.

Elimination

Mainly fecal as metabolites.

Interactions

No interactions reported yet.

Monitoring

Blood pressure with concurrent antihypertensives or alpha-blockers.

Patient counseling

Contraindicated with any nitrate, life-threatening hypotension. Caution with alpha-blockers, separate doses by ≥4 h. The "blue tint" visual side effect comes from PDE6 cross-reactivity in retinal cones.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

Avanafil, Tadalafil, Vardenafil

References

Summary
Classes
PDE5 Inhibitor
Common uses
Erectile dysfunction0, Pulmonary arterial hypertension0
Pharmacy
Starting dose
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH)
Preparations
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio)
US FDA Max
100 mg/d (ED); 20 mg TID (PAH)
Pharmacology
Routes
Oral, IV (Revatio)
Onset
30–60 min
Duration
~4 h
Half-life
~4 h
Bioavailability
~40%
Pregnancy
Category B
Legal status
Rx-only in US
Purported mechanism
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation.